Durect Corp (DRRX)

$1.91 -0.02 (-1.04%)
Market Cap 59.31M
Revenue (ttm) 2.03M
Net Income (ttm) -8.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -409.85%
Debt to Equity Ratio 0.00
Volume 2,787,600
Avg Vol 1,467,000
Day's Range N/A - N/A
Shares Out 31.05M
Stochastic %K 14%
Beta 0.92
Analysts Hold
Price Target $2.50

Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product candidate includes larsucosterol, an endogenous, orally bioavailable small molecule to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as for the treatment of patients with metabolic dysfunction-associated steatohepatitis. The company also offers POSIMIR,...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 408 777 1417
Fax: 408 777 3577
Address:
10240 Bubb Road, Cupertino, United States
brunoq14
brunoq14 Sep. 12 at 12:31 PM
$DRRX Goodbye Durect. A merger takes care of the rest of the shares.
0 · Reply
LeftyT
LeftyT Sep. 11 at 1:57 PM
$DRRX Well folks, 62% of shareholders tendered their shares so it's a done deal now. We all get $1.75 for each of our shares and a CVR from Bausch for each share we own. I wish Bausch Health (BHC) the best success in rapidly advancing Larsucosteral through a P3 and FDA approval. This drug has great potential IMHO and many, many lives could be saved with its approval. All the best to Mr Brown. He made a valiant effort to get this across the finish line. Now he can enjoy his retirement and watch a real pharma company take this to market. He will have a ton of CVR's from his shares, so you know he'll do whatever he can to help them advance this drug quickly.
0 · Reply
TwongStocks
TwongStocks Sep. 11 at 12:41 PM
$BHC Completes Acquisition of $DRRX, Expanding Late-stage Liver Disease Portfolio https://www.prnewswire.com/news-releases/bausch-health-completes-acquisition-of-durect-corporation-expanding-late-stage-liver-disease-portfolio-302553904.html DRRX shares were halted last night by NASDAQ. Shareholders will receive $1.75 and a CVR per share. If you owned 1000 DRRX, you will get $1750 and 1000 CVRs in your account. May take a few days for brokers to process the transaction into your accounts.
0 · Reply
bnjhnsn
bnjhnsn Sep. 11 at 12:10 PM
$DRRX well folks, it looks like the deal is done. Take your shiny pennies and dont lose track of those CVR's. Best of luck all!
0 · Reply
FreeBeerTomorrow
FreeBeerTomorrow Sep. 11 at 7:50 AM
$DRRX DRRX Tender Offer: Bausch Health is in the process of acquiring DRRX through a tender offer. They have offered to buy all outstanding shares of DRRX for $1.75 per share in cash, plus a contingent value right (CVR) that could provide additional payments based on future sales milestones. ​Tender Offer Expiration: The most recent public announcement indicates that the tender offer was extended to expire at 5:00 p.m. New York City time on September 10, 2025. ​Merger After Tender Offer: The definitive merger agreement states that as soon as practicable after the tender offer is successfully completed (meaning Bausch Health acquires a majority of the outstanding shares), Bausch Health will merge its subsidiary with and into DURECT. Any remaining shares of DRRX will be converted into the right to receive the same per-share consideration ($1.75 cash plus the CVR).
0 · Reply
mpcfishn
mpcfishn Sep. 11 at 1:37 AM
$DRRX im not understanding what's going on, will I lose my shares? How does this work? I'm using RH.
1 · Reply
LeftyT
LeftyT Sep. 10 at 5:36 PM
$DRRX So how does this work???? According to yesterday's Form 4 the CFO gets 110,000 sh stock option grant w/ a strike of 1.30/sh just 2 days before the tender off deadline. "The option will vest and become exercisable in installments of one- sixteenth of the total number of shares at the end of each 3 month period following the grant date". Are these options essentially worthless, or is there a clause that allows for complete vesting upon significant (already agreed to) ownership change? Inquiring minds want to know!!! http://archive.fast-edgar.com/20250909/AA2Z5G23ZC22LZ78222N2Z429P5UZK22ZN72
2 · Reply
Nabors5
Nabors5 Sep. 9 at 2:39 AM
$DRRX If I do nothing with my current shares does that mean I am accepting the tinder offer? Do the current Drrx shares I own transfer to BHC shares?
1 · Reply
Nabors5
Nabors5 Sep. 9 at 2:36 AM
$DRRX
0 · Reply
TwongStocks
TwongStocks Sep. 8 at 6:00 PM
$DRRX NASDAQ Equity Corporate Actions Alert # 2025 - 495 Information Regarding the Tender Offer of DURECT Corporation (DRRX) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-495 The tender offer by Bausch Health Companies Inc. (NYSE: BHC) to acquire all of the outstanding common stock of DURECT Corporation (DRRX) is scheduled to expire one minute after 5:00 p.m. ET, on September 10, 2025, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on September 11, 2025. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on September 10, 2025. If the merger closes as planned, the stock will remain halted on the day of closing (September 11) and will be suspended effective September 12, 2025. Tender offer: DRRX shareholders will receive $1.75 for each share held, plus one non-transferable contingent value right (CVR).
0 · Reply
Latest News on DRRX
Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025

Aug 26, 2025, 8:00 AM EDT - 17 days ago

Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025

BHC

DURECT Corporation Reports Second Quarter 2025 Financial Results and Provides Update on Proposed Acquisition by Bausch Health

Aug 12, 2025, 4:30 PM EDT - 4 weeks ago

DURECT Corporation Reports Second Quarter 2025 Financial Results and Provides Update on Proposed Acquisition by Bausch Health

Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout

Jul 29, 2025, 2:21 PM EDT - 6 weeks ago

Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout

BHC

Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease

Jul 29, 2025, 7:00 AM EDT - 6 weeks ago

Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease

BHC

DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 4:05 PM EDT - 4 months ago

DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

DURECT Corporation (DRRX) Q4 2024 Earnings Call Transcript

Mar 26, 2025, 8:04 PM EDT - 6 months ago

DURECT Corporation (DRRX) Q4 2024 Earnings Call Transcript

DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 26, 2025, 4:05 PM EDT - 6 months ago

DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update

Mar 19, 2025, 4:30 PM EDT - 6 months ago

DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update

DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 7:30 AM EST - 7 months ago

DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence

Jan 28, 2025, 10:09 AM EST - 8 months ago

DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence

DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million

Nov 25, 2024, 6:00 AM EST - 10 months ago

DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million

DURECT Corporation (DRRX) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 10:17 PM EST - 10 months ago

DURECT Corporation (DRRX) Q3 2024 Earnings Call Transcript

DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 13, 2024, 4:01 PM EST - 10 months ago

DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update

DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update

Nov 6, 2024, 4:45 PM EST - 11 months ago

DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update

DURECT Corporation to Present Data on Larsucosterol at The Liver Meeting 2024

Oct 17, 2024, 8:30 AM EDT - 11 months ago

DURECT Corporation to Present Data on Larsucosterol at The Liver Meeting 2024

DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis

Sep 25, 2024, 8:00 AM EDT - 1 year ago

DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis

DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference

Sep 4, 2024, 4:30 PM EDT - 1 year ago

DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference

DURECT Corporation (DRRX) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 8:42 PM EDT - 1 year ago

DURECT Corporation (DRRX) Q2 2024 Earnings Call Transcript

DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update

Aug 13, 2024, 4:01 PM EDT - 1 year ago

DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update

DURECT Corporation to Announce Second Quarter 2024 Financial Results and Provide a Business Update

Aug 7, 2024, 4:30 PM EDT - 1 year ago

DURECT Corporation to Announce Second Quarter 2024 Financial Results and Provide a Business Update

DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis

May 21, 2024, 8:00 AM EDT - 1 year ago

DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis

DURECT Corporation (DRRX) Q1 2024 Earnings Call Transcript

May 13, 2024, 9:54 PM EDT - 1 year ago

DURECT Corporation (DRRX) Q1 2024 Earnings Call Transcript

DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update

May 13, 2024, 4:05 PM EDT - 1 year ago

DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update

DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update

May 7, 2024, 4:30 PM EDT - 1 year ago

DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update

DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis

Apr 30, 2024, 7:00 AM EDT - 1 year ago

DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis

DURECT Corporation (DRRX) Q4 2023 Earnings Call Transcript

Mar 27, 2024, 6:07 PM EDT - 1 year ago

DURECT Corporation (DRRX) Q4 2023 Earnings Call Transcript

DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 27, 2024, 4:01 PM EDT - 1 year ago

DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

Mar 20, 2024, 4:30 PM EDT - 1 year ago

DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada

Mar 4, 2024, 7:00 AM EST - 1 year ago

DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada

DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 7, 2024, 6:48 PM EST - 1 year ago

DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Top 3 Health Care Stocks That Are Preparing To Pump This Month - Durect (NASDAQ:DRRX), Aadi Bioscience (NASDAQ:AADI)

Dec 18, 2023, 7:39 AM EST - 1 year ago

Top 3 Health Care Stocks That Are Preparing To Pump This Month - Durect (NASDAQ:DRRX), Aadi Bioscience (NASDAQ:AADI)

DURECT Corporation (DRRX) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 6:50 PM EST - 1 year ago

DURECT Corporation (DRRX) Q3 2023 Earnings Call Transcript

DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update

Nov 13, 2023, 4:05 PM EST - 1 year ago

DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update

DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update

Nov 9, 2023, 4:30 PM EST - 2 years ago

DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update

DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality

Nov 7, 2023, 4:01 PM EST - 2 years ago

DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality

DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis

Sep 7, 2023, 7:00 AM EDT - 2 years ago

DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis

DURECT Corporation Announces Presentations in Upcoming Investor Conferences

Aug 31, 2023, 4:30 PM EDT - 2 years ago

DURECT Corporation Announces Presentations in Upcoming Investor Conferences

DURECT Corporation (DRRX) Q2 2023 Earnings Call Transcript

Aug 9, 2023, 8:22 PM EDT - 2 years ago

DURECT Corporation (DRRX) Q2 2023 Earnings Call Transcript

DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update

Aug 9, 2023, 4:05 PM EDT - 2 years ago

DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update

DURECT Corporation to Announce Second Quarter 2023 Financial Results and Provide a Business Update

Aug 3, 2023, 4:30 PM EDT - 2 years ago

DURECT Corporation to Announce Second Quarter 2023 Financial Results and Provide a Business Update

DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jul 20, 2023, 8:00 AM EDT - 2 years ago

DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis

Jun 7, 2023, 6:00 AM EDT - 2 years ago

DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis

DURECT Corporation (DRRX) Q1 2023 Earnings Call Transcript

May 8, 2023, 10:42 PM EDT - 2 years ago

DURECT Corporation (DRRX) Q1 2023 Earnings Call Transcript

DURECT Corporation Reports First Quarter 2023 Financial Results and Business Update

May 8, 2023, 4:05 PM EDT - 2 years ago

DURECT Corporation Reports First Quarter 2023 Financial Results and Business Update

DURECT Corporation to Announce First Quarter 2023 Financial Results and Provide Business Update on May 8

May 1, 2023, 7:03 PM EDT - 2 years ago

DURECT Corporation to Announce First Quarter 2023 Financial Results and Provide Business Update on May 8

DURECT Corporation to Host KOL Event on Alcohol-Associated Hepatitis

Apr 27, 2023, 5:11 PM EDT - 2 years ago

DURECT Corporation to Host KOL Event on Alcohol-Associated Hepatitis

DURECT Corporation to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference

Apr 25, 2023, 6:45 PM EDT - 2 years ago

DURECT Corporation to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference

DURECT Announces Peer-Reviewed Article Accepted for Publication with Additional Data from Previously Completed Phase 2a Study of Larsucosterol in Alcohol-Associated Hepatitis

Apr 10, 2023, 6:00 AM EDT - 2 years ago

DURECT Announces Peer-Reviewed Article Accepted for Publication with Additional Data from Previously Completed Phase 2a Study of Larsucosterol in Alcohol-Associated Hepatitis

brunoq14
brunoq14 Sep. 12 at 12:31 PM
$DRRX Goodbye Durect. A merger takes care of the rest of the shares.
0 · Reply
LeftyT
LeftyT Sep. 11 at 1:57 PM
$DRRX Well folks, 62% of shareholders tendered their shares so it's a done deal now. We all get $1.75 for each of our shares and a CVR from Bausch for each share we own. I wish Bausch Health (BHC) the best success in rapidly advancing Larsucosteral through a P3 and FDA approval. This drug has great potential IMHO and many, many lives could be saved with its approval. All the best to Mr Brown. He made a valiant effort to get this across the finish line. Now he can enjoy his retirement and watch a real pharma company take this to market. He will have a ton of CVR's from his shares, so you know he'll do whatever he can to help them advance this drug quickly.
0 · Reply
TwongStocks
TwongStocks Sep. 11 at 12:41 PM
$BHC Completes Acquisition of $DRRX, Expanding Late-stage Liver Disease Portfolio https://www.prnewswire.com/news-releases/bausch-health-completes-acquisition-of-durect-corporation-expanding-late-stage-liver-disease-portfolio-302553904.html DRRX shares were halted last night by NASDAQ. Shareholders will receive $1.75 and a CVR per share. If you owned 1000 DRRX, you will get $1750 and 1000 CVRs in your account. May take a few days for brokers to process the transaction into your accounts.
0 · Reply
bnjhnsn
bnjhnsn Sep. 11 at 12:10 PM
$DRRX well folks, it looks like the deal is done. Take your shiny pennies and dont lose track of those CVR's. Best of luck all!
0 · Reply
FreeBeerTomorrow
FreeBeerTomorrow Sep. 11 at 7:50 AM
$DRRX DRRX Tender Offer: Bausch Health is in the process of acquiring DRRX through a tender offer. They have offered to buy all outstanding shares of DRRX for $1.75 per share in cash, plus a contingent value right (CVR) that could provide additional payments based on future sales milestones. ​Tender Offer Expiration: The most recent public announcement indicates that the tender offer was extended to expire at 5:00 p.m. New York City time on September 10, 2025. ​Merger After Tender Offer: The definitive merger agreement states that as soon as practicable after the tender offer is successfully completed (meaning Bausch Health acquires a majority of the outstanding shares), Bausch Health will merge its subsidiary with and into DURECT. Any remaining shares of DRRX will be converted into the right to receive the same per-share consideration ($1.75 cash plus the CVR).
0 · Reply
mpcfishn
mpcfishn Sep. 11 at 1:37 AM
$DRRX im not understanding what's going on, will I lose my shares? How does this work? I'm using RH.
1 · Reply
LeftyT
LeftyT Sep. 10 at 5:36 PM
$DRRX So how does this work???? According to yesterday's Form 4 the CFO gets 110,000 sh stock option grant w/ a strike of 1.30/sh just 2 days before the tender off deadline. "The option will vest and become exercisable in installments of one- sixteenth of the total number of shares at the end of each 3 month period following the grant date". Are these options essentially worthless, or is there a clause that allows for complete vesting upon significant (already agreed to) ownership change? Inquiring minds want to know!!! http://archive.fast-edgar.com/20250909/AA2Z5G23ZC22LZ78222N2Z429P5UZK22ZN72
2 · Reply
Nabors5
Nabors5 Sep. 9 at 2:39 AM
$DRRX If I do nothing with my current shares does that mean I am accepting the tinder offer? Do the current Drrx shares I own transfer to BHC shares?
1 · Reply
Nabors5
Nabors5 Sep. 9 at 2:36 AM
$DRRX
0 · Reply
TwongStocks
TwongStocks Sep. 8 at 6:00 PM
$DRRX NASDAQ Equity Corporate Actions Alert # 2025 - 495 Information Regarding the Tender Offer of DURECT Corporation (DRRX) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-495 The tender offer by Bausch Health Companies Inc. (NYSE: BHC) to acquire all of the outstanding common stock of DURECT Corporation (DRRX) is scheduled to expire one minute after 5:00 p.m. ET, on September 10, 2025, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on September 11, 2025. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on September 10, 2025. If the merger closes as planned, the stock will remain halted on the day of closing (September 11) and will be suspended effective September 12, 2025. Tender offer: DRRX shareholders will receive $1.75 for each share held, plus one non-transferable contingent value right (CVR).
0 · Reply
bnjhnsn
bnjhnsn Sep. 7 at 9:06 PM
$DRRX should be an interesting week as the deal likely moves forward. Unless there are unforseen obstacles.
0 · Reply
KINGSPARTAN
KINGSPARTAN Sep. 3 at 7:30 PM
$DRRX as already stated in my opinion the CVR’s are worth very little. Currently, the Market is only valuing them at roughly .17-.19 per CVR based on how this has been trading recently. Ask your why Mr. Scott and other potential large investors are not scooping up tons of shares if they thought the CVR’s had any kind of significant value. Curious if associates within the organization are buying large quantities. If there was any true, significant value to these I would believe there would be many trying to gather up shares for a potential huge payout. There are typically things behind the scenes that the average investor does not know about.
1 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 3 at 11:47 AM
$DRRX Outstanding article that hits the mark on DRRX's current state. So if you want to refresh your DRRX insights or learn about DRRX from scratch, this is a must read. https://beyondspx.com/quote/DRRX/durect-corporation-betting-on-an-epigenetic-breakthrough-in-alcohol-associated-hepatitis-nasdaq-drrx#analysis
0 · Reply
KINGSPARTAN
KINGSPARTAN Aug. 29 at 5:58 PM
$DRRX Folks, you do realize the tender offer is weak. An offer of .175 pre-reverse split??? An offer of $10 with the CVR’s would have been more acceptable. That is $1 pre-reverse split. If the drug is as good as Durect management say why is it only selling for $63 Million? That price also includes the acquiring company to get remaining cash on hand, Posimir (say, what happened to this anyway) and all other assets. In my opinion if the current TO goes thru they will shelve Larsucosterol and those CVR’s will turn out worthless. Just sayin’……..
1 · Reply
msufans
msufans Aug. 29 at 2:49 PM
$DRRX i just accepted the TO through Charles Schwab.
2 · Reply
bnjhnsn
bnjhnsn Aug. 26 at 1:15 PM
$DRRX new company filing. Not sure what to make of it.
0 · Reply
ExecutiveEdge
ExecutiveEdge Aug. 26 at 3:04 AM
Top watch ticker - -- TGL, setting up for one of those out of these world moves, news could be anyday according to Prs, also $18 book value and $12 true value, forming a LONGTERM reversal. $DRRX $INHD $EPIX $MENS ..
0 · Reply
phillysea12
phillysea12 Aug. 25 at 7:23 PM
$DRRX where can I find how many outstanding share are there for Drrx?
1 · Reply
Pipelinepivots
Pipelinepivots Aug. 25 at 2:19 AM
watch TGL, 3m float, $18 book value, $12 intrinsic, millions of volume and shorts in this! Everyone is buying and holding for a run to $6-$8 Not that many people know about it yet! KEEP ON WATCH 🚨🚨……… $ZEPP $DRRX $CGTX $BSLK ./
0 · Reply
TensorSecurities
TensorSecurities Aug. 23 at 11:18 AM
$DRRX DURECT Corporation is facing pharmaceutical development challenges and partnership needs
0 · Reply
bnjhnsn
bnjhnsn Aug. 22 at 1:55 PM
$DRRX r scott Asen is accumulating CVR's
1 · Reply
bnjhnsn
bnjhnsn Aug. 21 at 6:36 PM
$DRRX excluding any previous losses, if the First sales goal is realized, the CVR pays 20x your investment. If the higher sales goal is reached within 10 years of product selling, then it pays an additional 53x the investment cost. (15 cents) They must really think that this is a long shot.
3 · Reply